New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...